Forbes Highlights Digital Diagnostics as a Key Player in AI-Powered Eye Care
Forbes has recognized Digital Diagnostics in the article, “The Eye Exam Is Becoming an AI Exam.” The article highlights how artificial intelligence is reshaping eye care and recognizes Digital Diagnostics as a key player in that transformation.
Bringing AI to the Point-of-Care
According to Forbes, autonomous AI for diabetic retinopathy (DR) diagnosis is one of the clearest real-world successes of AI moving from concept to clinical use. Digital Diagnostics’ Founder and Executive Chairman, Michael D. Abràmoff, MD, PhD, is credited with pioneering the work that led to LumineticsCore®, which was granted the first FDA De Novo clearance for an autonomous AI system in 2018. Today, LumineticsCore is in use across the U.S. and is reimbursable using CPT code 92229.
“The brutal truth is that people are losing sight because of delays,” according to a quote by a Professor of Artificial Medical Intelligence at UCL Institute of Ophthalmology and a Consultant Ophthalmologist at Moorfields Eye Hospital. This statement underscores why timely diagnosis is critical – and why solutions like LumineticsCore are so essential. By enabling providers to diagnose DR during a point-of-care visit, autonomous AI can reduce delays dramatically, allowing for earlier diagnosis, faster treatment, and fewer patients at risk of preventable vision loss.
How AI Is Moving Closer to Patients
The Forbes article outlines the evolution of healthcare AI:
- 2018: FDA De Novo clearance for autonomous AI for DR diagnosis [LumineticsCore]
- 2021: CPT code 92229 created for the reimbursement of autonomous retinal imaging
- 2024: De Novo clearance for home OCT with AI to remotely monitor AMD
At Digital Diagnostics, we’re proud to play a role in transforming healthcare by developing technology that integrates into primary care workflows to meet patients where they are.
Making Care More Accessible and Equitable
AI can only reach its full potential when it’s accessible. Forbes highlights Singapore’s “AI-first, expert-second” screening program for diabetic retinopathy. In this model, fundus cameras in community clinics capture images that are automatically analyzed by AI, and only uncertain or positive cases are escalated to specialists. This approach can help streamline referrals, reduce unnecessary specialist visits, and deliver results in minutes, demonstrating that when AI and clinical workflows align, access can improve dramatically. The article also points to a future where AI not only detects disease but helps guide treatment timing, personalize care, and even identify candidates for emerging therapies.
Looking Ahead
At Digital Diagnostics, we’re focused on our mission to bringing high-quality, specialist-level diagnostics to where patients already receive care. We’re committed to transparency and continuous AI performance monitoring to help ensure every patient benefits from safe, effective, and accessible care. Our vision is to advance healthcare transformation by paving the way for ethically founded AI technology to become the new standard of care, increasing access to high-quality healthcare and improving patient outcomes.
Request a demo to learn more about how LumineticsCore brings high-quality diagnostics to the point-of-care.